Louisiana, Health Centers Seek Dismissal of Contract Pharmacy Law Challenge

AstraZeneca headquarters
AstraZeneca will discontinue a certain bottle dosage of its breast cancer drug Truqap (capiversatib) by the end of the year but allow 340B covered entities to replenish their supply with an equivalent dose in blister pack package form.
Attorneys representing the state of Louisiana and 340B providers urged a federal judge to dismiss AstraZeneca’s lawsuit against Louisiana’s contract [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Critics of 340B Urge Congressional Reforms of the Program

Edolphus Towns, Jr., a former congressman (D-N.Y.) who voted to create the 340B program, recently wrote a guest editorial calling for congressional reforms.
Critics of the 340B program, including a former congressman who voted to create the program, have written recent editorials urging [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Industry Insights Logo

Exploring Key Aspects of the 340B Program

SPONSORED CONTENT

The 340B drug pricing program allows covered entities serving vulnerable patient populations to buy medications at a discount. Since 1987, AIDS Healthcare Foundation has been on the frontline of the HIV response in the United States.  AHF cares for patients regardless

Read More »

A Tribute to Our Founding Editor in Chief from the Publisher and CEO

Ted Slafsky, publisher and CEO of 340B Report, calls retiring editor-in-chief Tom Mirga a "brilliant writer and reporter" in a tribute editorial.
When I thought about launching 340B Report, the first person I reached out to was Tom Mirga. Tom and I [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Column: Hospitals Are Not the Only 340B Providers Under Scrutiny

Ted Slafsky, publisher and CEO of 340B Report, writes the second part of his two-part column on the Senate "group of six" 340B discussion draft.
Veteran 340B observers were surprised to see that Sen. Bill Cassidy (R-La.) has expanded his 340B investigation into community health [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Exclusive

Lilly to Conduct HRSA-Approved Audit That Includes First-Time Look for Medicaid MCO Duplicate Discounts

Lilly
Eli Lilly is conducting government approved 340B provider audits that for the first time look for certain Medicaid health plan duplicate discounts.
Federal regulators have approved a first-time 340B provider audit by a drug manufacturer to examine processes to prevent duplicate discounts [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

CMS Defers Decision on Adding 340B Modifiers for Part D Drugs

CMS
In response to the ongoing Change Healthcare cyberattack, CMS will direct contractors to provide some accelerated payments to hospitals.
Federal regulators recently deferred a decision on whether to add identifiers to 340B drugs purchased under Medicare Part D. The [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Industry Insights Logo

Implementing for Success

SPONSORED CONTENT

After 30 years of serving vulnerable populations, the 340B Drug Pricing Program has grown considerably in scale and complexity. While it is arguably one of the most successful public/private partnerships in healthcare history, 340B is facing policy obstacles and headwinds that can make

Read More »

DeGette Seen as Possible Successor to Eshoo as Top Dem on House E&C Health Subcommittee

Rep. Diana DeGette (D-Colo.) is a possible candidate to succeed retiring Rep. Anna Eshoo (D-Calif.) as the ranking Democrat or chair of the House E&C Health Subcommittee.
Who will succeed retiring Rep. Anna Eshoo (D-Calif.) as top Democrat on the House Energy & Commerce (E&C) subcommittee that [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

Takeda Becomes 29th Drugmaker to Implement 340B Contract Pharmacy Restrictions

Takeda 340B
Japanese drugmaker Takeda announced its cancer medication Ninlaro will be subject to its 340B contract pharmacy policy.
Japanese pharmaceutical giant Takeda last Friday became the 29th drugmaker to place conditions on 340B pricing in the contract pharmacy [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »